Cardiovascular Systems Featuring Training Lab at VEITH 2012


Attendees Will Have Hands-on Opportunity to Experience Effectiveness of Orbital Atherectomy at Treating Complex Calcium

Cardiovascular Systems Featuring Training Lab at VEITH 2012

Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII), is offering 2012 VEITHsymposium™ attendees an opportunity to learn about the effectiveness of orbital atherectomy in treating peripheral arterial disease (PAD). Featuring live demos of the company’s revolutionary Orbital Atherectomy System, a hands-on training lab and the chance to engage with orbital atherectomy experts via CSIQ—the company’s official medical education program—attendees can experience firsthand what it takes to defeat complex arterial calcium.

Arterial calcification is a common, underdiagnosed condition with complicating factors—including a higher frequency of dissections and perforations—that pose a challenge for physicians treating PAD. Calcified lesions are estimated to be present in approximately 65 percent of the people treated annually for PAD.

Visit CSI at booth #1114/1116 9 a.m. – 5 p.m. Wednesday, Nov. 14, through Friday, Nov. 16.

PAD is a life-threatening condition where a fatty material called plaque builds up on the inside walls of the blood vessels that carry blood from the heart to legs and arms. The plaque buildup causes the arteries to harden and narrow (atherosclerosis), reducing blood flow to the legs. The risk of PAD increases if a person has one or several of the following: high blood pressure, abnormal cholesterol levels, diabetes, or personal history of heart disease, heart attack or stroke. PAD affects an estimated 8-12 million people in the United States. The disease prevalence increases with age and 12-20 percent of Americans age 65 and older suffer from PAD symptoms. As the U.S. population ages, the prevalence range could reach 16 million in those age 65 and older and 19 million overall by 2050.

Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company’s Orbital Atherectomy Systems treat calcified and fibrotic plaque in arterial vessels throughout the leg in a few minutes of treatment time, and address many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. The U.S. FDA granted 510(k) clearance for the use of the Diamondback Orbital Atherectomy System in August 2007. To date, nearly 100,000 of CSI’s devices have been sold to leading institutions across the United States. CSI has also commenced its ORBIT II Investigational Device Exemption clinical trial to evaluate the safety and effectiveness of its orbital technology in treating coronary arteries.

For more information, visit the company’s website at .